Use of an anti-aging composition in the preparation of a product for improving chronic fatigue syndrome

Abstract

The present application relates to the application of an anti-aging composition in the preparation of a product for improving chronic fatigue syndrome, the composition comprising ginsenosides, coenzyme Q10, pyrroloquinoline quinone, ergothioneine and tuckahoe polysaccharide. The present application creatively combines the five components to obtain an anti-aging composition for improving chronic fatigue, wherein coenzyme Q10 directly improves mitochondrial ATP production, pyrroloquinoline quinone increases the number of mitochondria, ergothioneine improves metabolic efficiency through NAD+ regeneration, ginsenosides restore the AMPK energy regulation system, and tuckahoe polysaccharide can improve digestion and absorption to provide logistical support. The five components cooperate with each other and have a synergistic effect, and they solve the problem of fatigue from five dimensions of energy production, energy regulation, organelle expansion, metabolic efficiency and nutrient absorption, forming a dual support of "traditional Chinese medicine experience + modern clinical evidence".

Description

Technical Field

[0001] This invention belongs to the field of functional food technology and relates to the application of an anti-aging composition in the preparation of products for improving chronic fatigue syndrome. Background Technology

[0002] Age-related fatigue syndrome (ADFS) is characterized by persistent physical and mental fatigue, lack of energy, worsening symptoms after activity, and a significant decline in exercise tolerance, severely impacting the quality of life of middle-aged and elderly individuals. The prevalence of ADFS in the general population is approximately 0.68%–1.40%, with a prevalence of about 12.54% in my country, and the onset is trending towards younger ages. Currently, there are no specific drugs for ADFS, and existing intervention methods have significant limitations.

[0003] Studies have shown that the core pathological mechanism of age-related fatigue syndrome involves multiple links: (1) Mitochondrial dysfunction leads to a decrease in ATP production, and the ATP content and oxidative phosphorylation efficiency in neutrophils are reduced, resulting in insufficient energy supply throughout the body; (2) The decrease in NAD+ level affects the energy metabolism regulation mediated by SIRT1, leading to the inhibition of mitochondrial biosynthesis and the accumulation of oxidative stress; (3) HPA axis dysfunction manifests as cortisol rhythm disorder, and the baseline HPA axis function is reduced, making it difficult for the body to recover effectively from physical and mental exhaustion; (4) The decline in spleen and stomach function affects nutrient absorption and energy conversion, forming a vicious cycle of "insufficient intake - conversion disorder - energy depletion".

[0004] Among existing interventions, central nervous system stimulants such as caffeine only provide short-term, superficial relief and cannot improve the fundamental defects in energy metabolism; single energy supplements such as B vitamins and coenzyme Q10 have limited targets and are difficult to systematically improve defects in multiple aspects; although traditional Chinese medicine for strengthening the spleen can partially alleviate symptoms by treating the spleen, its components are complex, its mechanisms are unclear, and its efficacy varies greatly among individuals. To date, no oral preparation has been reported that can systematically intervene in age-related fatigue syndrome from four dimensions: mitochondrial energy production, NAD+ / SIRT1 metabolic regulation, HPA axis stress recovery, and spleen and stomach nutritional conversion support.

[0005] Therefore, there is a clear clinical need and room for innovation in developing an oral composition that synergistically intervenes in age-related fatigue syndrome through multiple targets and mechanisms. Summary of the Invention

[0006] In view of the shortcomings of the prior art, the purpose of this invention is to provide an application of an anti-aging composition in the preparation of products for improving chronic fatigue syndrome.

[0007] To achieve this objective, the present invention employs the following technical solution: In a first aspect, the present invention provides an application of an anti-aging composition in the preparation of a product for improving chronic fatigue syndrome, the composition comprising: ginsenosides, coenzyme Q10, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide.

[0008] This invention creatively combines five components to obtain an anti-aging composition that can improve chronic fatigue. Coenzyme Q10 directly increases mitochondrial ATP production, pyrroloquinoline quinone increases mitochondrial numbers, ergothionein enhances metabolic efficiency through NAD+ regeneration, ginsenosides restore the AMPK energy regulation system, and Poria cocos polysaccharides improve digestion and absorption, providing logistical support. These five components work synergistically to address fatigue from five dimensions: energy production, energy regulation, organelle expansion, metabolic efficiency, and nutrient absorption, forming a dual support of "traditional Chinese medicine experience + modern clinical evidence."

[0009] Preferably, the anti-aging composition comprises, by weight, 1-30 parts of ginsenoside compounds (e.g., 1 part, 5 parts, 10 parts, 15 parts, 20 parts, 25 parts, 30 parts, etc.), 5-200 parts of coenzyme Q10 (e.g., 5 parts, 10 parts, 20 parts, 40 parts, 60 parts, 100 parts, 120 parts, 140 parts, 160 parts, 200 parts, etc.), 1-50 parts of pyrroloquinoline quinone (e.g., 1 part, 5 parts, 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, etc.), 5-100 parts of ergothioneine (e.g., 5 parts, 10 parts, 20 parts, 40 parts, 60 parts, 80 parts, 100 parts, etc.), and 1-100 parts of Poria cocos polysaccharide (e.g., 1 part, 10 parts, 20 parts, 40 parts, 60 parts, 80 parts, 100 parts, etc.).

[0010] Preferably, the ginsenoside compounds include any one or a combination of at least two of ginsenoside CK, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rh4, and ginsenoside Rg2.

[0011] Preferably, the ginsenoside compound is ginsenoside CK.

[0012] Preferably, the dosage form of the product includes any one of tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

[0013] Preferably, the product also includes excipients acceptable in the functional food field.

[0014] Preferably, the excipients acceptable in the functional food field include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

[0015] Secondly, the present invention provides an application of an anti-aging composition in the preparation of a product for improving chronic fatigue-related decline in exercise endurance, the composition comprising: ginsenosides, coenzyme Q10, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide.

[0016] Preferably, the anti-aging composition comprises, by weight, 1-30 parts of ginsenoside compounds (e.g., 1 part, 5 parts, 10 parts, 15 parts, 20 parts, 25 parts, 30 parts, etc.), 5-200 parts of coenzyme Q10 (e.g., 5 parts, 10 parts, 20 parts, 40 parts, 60 parts, 100 parts, 120 parts, 140 parts, 160 parts, 200 parts, etc.), 1-50 parts of pyrroloquinoline quinone (e.g., 1 part, 5 parts, 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, etc.), 5-100 parts of ergothioneine (e.g., 5 parts, 10 parts, 20 parts, 40 parts, 60 parts, 80 parts, 100 parts, etc.), and 1-100 parts of Poria cocos polysaccharide (e.g., 1 part, 10 parts, 20 parts, 40 parts, 60 parts, 80 parts, 100 parts, etc.).

[0017] All other specific point values ​​not listed above within the numerical ranges mentioned above can be selected and are all within the protection scope of this invention. For the sake of brevity, they will not be described in detail here.

[0018] Preferably, the ginsenoside compounds include any one or a combination of at least two of ginsenoside CK, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rh4, and ginsenoside Rg2.

[0019] Preferably, the ginsenoside compound is ginsenoside CK.

[0020] Preferably, the dosage form of the product includes any one of tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

[0021] Preferably, the product also includes excipients acceptable in the functional food field.

[0022] Preferably, the excipients acceptable in the functional food field include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

[0023] Compared with the prior art, the present invention has the following beneficial effects: This invention creatively combines five components to obtain an anti-aging composition that can improve chronic fatigue. Coenzyme Q10 directly increases mitochondrial ATP production, pyrroloquinoline quinone increases mitochondrial numbers, ergothionein enhances metabolic efficiency through NAD+ regeneration, ginsenosides restore the AMPK energy regulation system, and Poria cocos polysaccharides improve digestion and absorption, providing logistical support. These five components work synergistically to address fatigue from five dimensions: energy production, energy regulation, organelle expansion, metabolic efficiency, and nutrient absorption, forming a dual support of "traditional Chinese medicine experience + modern clinical evidence." Attached Figure Description

[0024] Figure 1 The time of exhaustion swimming in zebrafish was measured when the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 of the present invention were evaluated in a D-galactose-induced aging fatigue model of zebrafish. Figure 2 The total ATP content was measured when the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 of the present invention were evaluated in a D-galactose-induced zebrafish aging fatigue model. Figure 3 The time of exhaustion swimming in mice was measured when the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 of the present invention were evaluated in a mouse model of D-galactose-induced accelerated aging. Figure 4 The forelimb gripping force of mice was measured when the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 of the present invention were evaluated in a D-galactose-induced accelerated aging mouse model. Detailed Implementation

[0025] To further illustrate the technical means and effects of the present invention, the following describes the technical solution of the present invention in conjunction with preferred embodiments of the present invention. However, the present invention is not limited to the scope of the embodiments.

[0026] The relative molecular weight distribution of the Poria cocos polysaccharide used in this invention is 1.14 × 10⁻⁶. 4 ~8.671×10 5 The dispersion coefficient was 1.4; the polysaccharide content was determined to be ≥40% using the phenol-sulfuric acid method with pure Poria cocos polysaccharide as a reference.

[0027] Example 1 This embodiment provides an anti-aging composition, the preparation method of which is as follows: At 25°C, 10 parts of ginsenoside CK, 50 parts of coenzyme Q10, 20 parts of pyrroloquinoline quinone, 30 parts of ergothioneine, and 50 parts of Poria cocos polysaccharide were mixed to obtain the anti-aging composition.

[0028] Example 2 This embodiment provides an anti-aging composition, the preparation method of which is as follows: At 25°C, 12 parts of ginsenoside CK, 45 parts of coenzyme Q10, 20 parts of pyrroloquinoline quinone, 40 parts of ergothioneine, and 30 parts of Poria cocos polysaccharide were mixed to obtain the anti-aging composition.

[0029] Example 3 This embodiment provides an anti-aging composition, the preparation method of which is as follows: At 25°C, 8 parts of ginsenoside CK, 40 parts of coenzyme Q10, 30 parts of pyrroloquinoline quinone, 20 parts of ergothioneine, and 50 parts of Poria cocos polysaccharide were mixed to obtain the anti-aging composition.

[0030] Example 4 This embodiment provides an anti-aging composition. The preparation method differs from that of Example 1 only in that ginsenoside CK is replaced with an equal amount of ginsenoside Rb1, while all other conditions remain unchanged.

[0031] Example 5 This embodiment provides an anti-aging composition. The preparation method differs from that of Example 1 only in that ginsenoside CK is replaced with an equal amount of ginsenoside Rg2, while all other conditions remain unchanged.

[0032] Comparative Example 1 This comparative example provides an anti-aging composition. The preparation method differs from that of Example 1 only in that ginsenoside CK is not added, and the reduced amount of ginsenoside CK is proportionally allocated to coenzyme Q10, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide, while all other conditions remain unchanged.

[0033] Comparative Example 2 This comparative example provides an anti-aging composition. The preparation method differs from that of Example 1 only in that coenzyme Q10 is not added, and the reduced amount of coenzyme Q10 is proportionally allocated to ginsenoside CK, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide, while all other conditions remain unchanged.

[0034] Comparative Example 3 This comparative example provides an anti-aging composition. The preparation method differs from that of Example 1 only in that pyrroloquinoline quinone is not added, and the reduced amount of pyrroloquinoline quinone is proportionally allocated to ginsenoside CK, coenzyme Q10, ergothioneine, and poria cocos polysaccharide, while other conditions remain unchanged.

[0035] Comparative Example 4 This comparative example provides an anti-aging composition. The preparation method differs from that of Example 1 only in that ergothioneine is not added, and the reduced amount of ergothioneine is proportionally allocated to ginsenoside CK, coenzyme Q10, pyrroloquinoline quinone, and poria cocos polysaccharide, while all other conditions remain unchanged.

[0036] Comparative Example 5 This comparative example provides an anti-aging composition. The only difference between this composition and Example 1 is that Poria cocos polysaccharide is not added. Instead, the reduced amount of Poria cocos polysaccharide is proportionally allocated to ginsenoside CK, coenzyme Q10, pyrroloquinoline quinone, and ergothioneine. All other conditions remain unchanged.

[0037] Test Example 1 This test case evaluates the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 using a D-galactose-induced zebrafish aging fatigue model.

[0038] Healthy wild-type AB strain zebrafish, 3 days post-fertilization (3 dpf), were selected and acclimatized in a standard recirculating aquaculture system for 3 days. The zebrafish were then transferred to a 400 mg / L D-galactose solution and cultured for 4 weeks to establish an aging fatigue model. The D-galactose-containing water was changed every 3 days. The successful establishment of the model was determined by the following criteria: compared to the normal control group, the zebrafish in the model control group exhibited signs of aging such as slower swimming, sinking to the bottom, and scale loss; their exhaustive swimming time was significantly shortened; and their overall ATP content was significantly reduced.

[0039] Zebrafish that successfully underwent modeling were randomly divided into 12 groups, with 15 fish in each group (5 fish per well, 3 parallel wells per group). The groups were configured as follows: normal control group (NC, normal culture water), model control group (MC, D-galactose modeling without drug administration), Examples 1-3 groups, and Comparative Examples 1-5 groups (D-galactose modeling + samples from each group). The test sample for each drug administration group was dissolved in the culture water at a concentration of 28 mg / L. The drug-containing culture water was changed daily for 4 consecutive weeks. The normal control group and the model control group received an equal volume of culture water.

[0040] Exhaustion swimming time determination: Four weeks after drug administration, five zebrafish were randomly selected from each group for exhaustion swimming tests. Each zebrafish was transferred to a circular swimming test apparatus (20 cm in diameter, 15 cm in water depth, 28±1℃). The water flow speed was set to 10 cm / s, and the zebrafish was continuously driven to swim against the current. Timing was recorded from the moment the zebrafish entered the water, recording the time spent actively swimming against the current. Exhaustion was defined as the time when the zebrafish stopped swimming against the current, was swept to the end of the apparatus, and could not resume swimming against the current within 10 seconds. This recorded time was the exhaustion swimming time (unit: seconds). Each fish was tested once, and the average of the results from each group was taken as the exhaustion swimming time for that group. The test results are as follows: Figure 1 As shown in the figure, *** indicates that the normal control group and the model control group are compared with p<0.001; #, ##, and ### indicate that each group is compared with Example 1 with p<0.05, p<0.01, and p<0.001, respectively.

[0041] Whole ATP content determination: After the exhaustive swimming test, the remaining 10 zebrafish from each group were anesthetized and euthanized with 0.02% MS-222 solution. After washing with pre-cooled PBS buffer and drying the surface, the whole fish were placed in pre-cooled tissue lysis buffer and homogenized thoroughly using a glass homogenizer under ice bath conditions. The homogenate was centrifuged at 8000 g for 10 minutes at 4℃, and the supernatant was collected for analysis. The whole ATP content was determined using a biochemiluminescence ATP assay kit (luciferase method). Specific procedures were performed according to the kit instructions. ATP content is expressed as per gram of tissue (or per fish) (unit: nmol / g). The closer the ATP content is to the normal control group level, the more significant the effect of the test product in improving energy metabolism and alleviating aging fatigue. The test results are as follows: Figure 2 As shown in the figure, *** indicates that the normal control group and the model control group are compared with p<0.001; #, ##, and ### indicate that each group is compared with Example 1 with p<0.05, p<0.01, and p<0.001, respectively.

[0042] The results showed that after 4 weeks of D-galactose induction, the exhaustive swimming time and overall ATP content in the model control group were significantly shortened, indicating that the D-galactose-induced aging fatigue model was successfully established. After 4 weeks of continuous administration in groups 1-3 of Examples, the exhaustive swimming time and overall ATP content significantly recovered. These results demonstrate that the complete composition of this invention can effectively improve D-galactose-induced aging fatigue, restore mitochondrial ATP synthesis function, and enhance the exercise endurance of zebrafish. Changing the components of the composition of this invention or omitting any component will lead to a significant decrease in efficacy.

[0043] Test Example 2 This test case evaluates the anti-aging compositions of Examples 1-5 and Comparative Examples 1-5 using a D-galactose-induced accelerated aging mouse model.

[0044] Eight-week-old SPF-grade male C57BL / 6J mice, weighing 20-22 g, were selected and acclimatized for 7 days before the experiment. A subacute aging model was established by subcutaneous injection of D-galactose (prepared as a 5% solution with physiological saline) into the neck and back at a dose of 125 mg / kg body weight, once daily for 8 weeks. The normal control group received an equal volume of physiological saline. The successful establishment of the model was determined by a significant decrease in forelimb grip strength and a significantly shorter exhaustive swimming time compared to the normal control group, indicating successful model establishment.

[0045] Mice that successfully developed the model were randomly divided into 10 groups, with 6 mice in each group: normal control group (NC, treated with physiological saline), model control group (MC, D-galactose modeling + physiological saline), Example 1-3 groups, and Comparative Examples 1-5 groups. The test product was administered to each group at a dose of 50 mg / kg body weight via gavage once daily for 4 weeks, with an administration volume of 10 mL / kg. During the administration period, D-galactose modeling was maintained (125 mg / kg D-galactose was injected subcutaneously daily), and administration was carried out concurrently with modeling. The normal control group and the model control group were administered an equal volume of physiological saline via gavage.

[0046] Exhaustion swimming time determination: One hour after the last administration, mice were placed in a glass pool with a diameter of 25 cm, a water depth of 30 cm, and a water temperature of 25±1℃ for exhaustion swimming tests. A lead weight equivalent to 5% of the mouse's body weight was placed on the mouse's tail. The time from the moment the mouse entered the water until its head remained submerged for 5 seconds and could not resurface was recorded as the exhaustion swimming time (unit: seconds). Each mouse was measured once, and the average of the results from each group was taken as the exhaustion swimming time for that group. The test results are as follows: Figure 3 As shown in the figure, *, **, and *** indicate that each group is compared with the model control group, with p < 0.05, p < 0.01, and p < 0.001 respectively; #, ##, and ### indicate that compared with Example 1, p < 0.05, p < 0.01, and p < 0.001 respectively.

[0047] Forelimb gripping force measurement: A rat and mouse gripping force meter was used for measurement. Each mouse was weighed before the test, and the animals were brought into the testing room one hour prior to the test to acclimatize. The mouse's forelimb was placed on the grip bar of the gripping force meter, with the mouse's body horizontal to the sensor. The mouse's tail was gently grasped and pulled backward at a constant speed until the forelimb was completely released from the grip bar. The maximum reading displayed on the gripping force meter was recorded, and the force / body weight ratio (unit: N / g) was obtained by dividing the reading by the mouse's body weight. Each mouse was measured three times consecutively, with a 30-second interval between each measurement. The average value was taken as the forelimb gripping force value for that mouse. The test results are as follows: Figure 4As shown in the figure, *, **, and *** indicate that each group is compared with the model control group, with p < 0.05, p < 0.01, and p < 0.001 respectively; #, ##, and ### indicate that compared with Example 1, p < 0.05, p < 0.01, and p < 0.001 respectively.

[0048] The results showed that in the model control group, after 8 weeks of subcutaneous injection of D-galactose, the exhaustive swimming time was significantly shortened and the forelimb grip strength was significantly reduced, indicating that the D-galactose-induced aging model was successfully established. In Examples 1-3, after 4 weeks of continuous administration, both exhaustive swimming time and forelimb grip strength showed significant recovery. These results demonstrate that the complete composition of this invention can effectively reverse the D-galactose-induced age-related decline in exercise endurance and muscle strength. Changing the components of the composition of this invention or omitting any component will lead to a significant decrease in efficacy.

[0049] The applicant declares that the technical solution of this invention is illustrated by the above embodiments, but this invention is not limited to the above embodiments, that is, it does not mean that this invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of raw materials for the products of this invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of this invention.

[0050] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0051] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. The use of an anti-aging composition in the preparation of a product for improving chronic fatigue syndrome, characterized in that, The composition comprises: ginsenosides, coenzyme Q10, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide.

2. The application according to claim 1, characterized in that, The anti-aging composition comprises, by weight, 1-30 parts ginsenosides, 5-200 parts coenzyme Q10, 1-50 parts pyrroloquinoline quinone, 5-100 parts ergothioneine, and 1-100 parts Poria cocos polysaccharide.

3. The application according to claim 1 or 2, characterized in that, The ginsenoside compounds include any one or a combination of at least two of ginsenoside CK, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rh4, and ginsenoside Rg2.

4. The application according to any one of claims 1-3, characterized in that, The ginsenoside compound is ginsenoside CK.

5. The application according to any one of claims 1-4, characterized in that, The dosage form of the product includes any one of tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills; Preferably, the product further includes excipients acceptable in the functional food field; Preferably, the excipients acceptable in the functional food field include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

6. The use of an anti-aging composition in the preparation of a product for improving chronic fatigue-related decline in exercise endurance, characterized in that, The composition comprises: ginsenosides, coenzyme Q10, pyrroloquinoline quinone, ergothioneine, and poria cocos polysaccharide.

7. The application according to claim 6, characterized in that, The anti-aging composition comprises, by weight, 1-30 parts ginsenosides, 5-200 parts coenzyme Q10, 1-50 parts pyrroloquinoline quinone, 5-100 parts ergothioneine, and 1-100 parts Poria cocos polysaccharide.

8. The application according to claim 6 or 7, characterized in that, The ginsenoside compounds include any one or a combination of at least two of ginsenoside CK, ginsenoside Rb1, ginsenoside Rb2, ginsenoside Rh4, and ginsenoside Rg2.

9. The application according to any one of claims 6-8, characterized in that, The ginsenoside compound is ginsenoside CK.

10. The application according to any one of claims 6-9, characterized in that, The dosage form of the product includes any one of tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills; Preferably, the product further includes excipients acceptable in the functional food field; Preferably, the excipients acceptable in the functional food field include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

Images